<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562872</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_DSM265_14_03</org_study_id>
    <secondary_id>CDMRP-PR130402</secondary_id>
    <nct_id>NCT02562872</nct_id>
  </id_info>
  <brief_title>DSM265 Prophylaxis of Plasmodium Falciparum Malaria</brief_title>
  <official_title>Proof-of-concept, Single Center Study in Healthy Adult Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Prophylactic Activity of Single Dose DSM265 in a Controlled Human Malarial Infection Challenge Either by Direct Venous Inoculation of Plasmodium Falciparum Sporozoites or Mosquito-borne Plasmodium Falciparum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Infectious Disease Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265
      including up to two cohorts of healthy male and female volunteers aged 18 to 45 years.

      The study will be conducted into two sequential parts (Cohort 1 and Cohorts 2a and 2b).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohort 1:

        -  Controlled human malaria infection on Day 0 (Direct Venous Inoculation of 3200
           cryopreserved Plasmodium falciparum sporozoites)

        -  Drug administration on Day -3

        -  8 subjects: 6 DSM265 400 mg: 2 matching placebo Clinical safety review of Cohort 1 in
           order to proceed to Cohorts 2a and 2b

      Cohort 2a:

        -  Controlled human malaria infection on Day 0 (Direct Venous Inoculation of 3200
           cryopreserved Plasmodium falciparum sporozoites)

        -  Drug administration on Day -X (to be defined following safety and pharmacokinetic data)

        -  8 subjects: 6 DSM265 400 mg: 2 matching placebo

      Cohort 2b:

        -  Controlled human malaria infection on Day 0 (infected mosquito bite)

        -  Drug administration on Day -X (to be defined following safety and pharmacokinetic data)

        -  8 subjects: 6 DSM265 400 mg: 2 matching placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with positive parasitemia</measure>
    <time_frame>28 days</time_frame>
    <description>positive parasitemia detected by qRT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time interval between challenge and the first positive parasitemia</measure>
    <time_frame>28 days</time_frame>
    <description>Time from infection to peripheral parasitemia (qRT-PCR) in DSM265 / placebo treated subjects in each cohort given as a geometric mean [days]</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Active DSM265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a Active DSM265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b Active DSM265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSM265</intervention_name>
    <description>DSM265 400 mg single oral dose</description>
    <arm_group_label>Cohort 1 Active DSM265</arm_group_label>
    <arm_group_label>Cohort 2a Active DSM265</arm_group_label>
    <arm_group_label>Cohort 2b Active DSM265</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match DSM265, single oral dose</description>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Cohort 2a Placebo</arm_group_label>
    <arm_group_label>Cohort 2b Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sporozoites</intervention_name>
    <description>Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites</description>
    <arm_group_label>Cohort 1 Active DSM265</arm_group_label>
    <arm_group_label>Cohort 1 Placebo</arm_group_label>
    <arm_group_label>Cohort 2a Active DSM265</arm_group_label>
    <arm_group_label>Cohort 2a Placebo</arm_group_label>
    <other_name>PfSPZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infective mosquito bite</intervention_name>
    <description>Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum</description>
    <arm_group_label>Cohort 2b Active DSM265</arm_group_label>
    <arm_group_label>Cohort 2b Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Good health based on medical history and physical examination

          -  body mass index &gt;18 and &lt;30kg/m2

          -  Laboratory results without clinically significant findings within 60 days

          -  Males must use medically acceptable form of contraception from the dose of
             DSM265/Placebo for 120 days

          -  Women must be of non-child bearing potential or willing and able to practice one of
             the required continuous acceptable methods of contraception and have negative
             pregnancy tests

          -  Able &amp; willing to comply with all study requirements throughout the study

          -  Agree to undergo all study procedures, attend all study visits and stay overnight for
             observation if required, to last follow-up visit

          -  Willing to undergo a controlled human malaria infection by mosquito bites /
             inoculation

          -  Able and willing to answer all questions on informed consent correctly, and to sign
             the informed consent form

          -  Reachable constantly by mobile phone or email throughout the study period

          -  Refrain from blood donation throughout the study

          -  Willing to take atovaquone-proguanil, Chloroquine or other registered antimalarial

        Exclusion Criteria:

          -  Any history of malaria; any severe reactions to mosquito or insect bites; any history
             of anaphylaxis

          -  Plans to travel to malaria endemic region during the study period

          -  Previous participation in any malaria vaccine study or controlled human malaria
             infection study

          -  Participation in any other clinical study within 30 days of enrollment or plan to
             participate in another investigational vaccine/drug research during the study

          -  Breastfeeding or planning to become pregnant during the time of the study

          -  Positive Human Immunodeficiency Virus, Hepatitis B or C tests

          -  Any confirmed/suspected immunosuppressive or immunodeficient state

          -  History of serious psychiatric condition that may affect participation in the study,
             or history of convulsions, seizures, or of severe head trauma

          -  Symptoms, physical signs or laboratory values suggestive of systemic disorders

          -  History of cancer (except basal cell carcinoma of the skin)

          -  History of arrhythmias or documented prolonged QTcF-interval (&gt;450 msec) or 12-lead
             ECG demonstrating specific abnormalities

          -  Moderate risk or higher for cardiovascular event within 5 years (&gt;10%)

          -  Positive family history in 1st or 2nd degree relative &lt;50 years for cardiac disease,
             or history of, or known active cardiac disease

          -  history of: psoriasis or porphyria which may be exacerbated by chloroquine;
             splenectomy, or sickle cell anaemia or other red blood cell disorders; allergy or
             contra-indication to chloroquine or atovaquone-proguanil

          -  Treatment with an investigational drug within 28 days or 5 half-lives of study
             medication; use of any drugs or dietary supplements within 7 days or 5 half-lives
             prior to study medication. Herbal supplements must be discontinued at least 28 days
             prior to study medication. As an exception, acetaminophen or ibuprofen may be used as
             approved by the investigator

          -  Use of any prohibited medication

          -  Grapefruit or product containing grapefruit from28 days before study medication or
             throughout the study

          -  History of drug or alcohol abuse within 12 months prior to dosing, or laboratory
             evidence of abuse

          -  Current smoking of more than 10 cigarettes or equivalent per day

          -  Plan for major surgery between enrolment and study completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James G Kublin, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center - Prevention Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Controlled</keyword>
  <keyword>Human</keyword>
  <keyword>Malaria</keyword>
  <keyword>Infection</keyword>
  <keyword>Healthy</keyword>
  <keyword>Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

